Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
Key Points
Key Points
- Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
- NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.
Treatment
...reatmen...
...For Patients with Stage II to IVA Nasoph...
...ation 1.1For all nasopharyngeal carc...
...ndation 1.2For all NPC patients, both sequ...
...1.3For all NPC patients, a prescri...
...ommendation 1.4For all NPC patients, gross tum...
...tion 1.5For NPC patients who have undergon...
...1.6The delineation of elective nodal volumes shou...
...otherapy Sequence...
...2.1For T2N0 (AJCC 8th) NPC patients, chemothe...
...mendation 2.2For T1-2N1 (AJCC 8th) N...
...ation 2.3For Stage III–IVA (except T3N0) (A...
...2.4For Stage III–IVA (except T3N0) (AJ...
Recommendation 2.5For T3N0 (AJCC 8th) NPC pati...
...ncurrent Chemotherapy...
...ndation 3.1For all NPC patients without contrai...
...ndation 3.2For all NPC patients without con...
...n 3.3For NPC patients with a contra...
...tion 3.4For NPC patients with a contraindicat...
...duction Chemother...
...commendation 4.1For all NPC patients receivin...
...commendation 4.2For NPC patients receiving ind...
...n 4.3For NPC patients receiving in...
...vant Chemother...
...5.1For all NPC patients receiving...
...mendation 5.2For all NPC patients receivin...
...endation 5.3For all NPC patients re...
...1. Stage II to IVA Nasopharyngeal Carcinoma...